ReviewNutrients2023
Recent Advances in Nutraceuticals for the Treatment of Sarcopenic Obesity.
Review in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Improving Lipid Profiles ThroughFoods (Basel, Switzerland) · 2026Review
- Immunometabolic mechanisms of osteosarcopenic obesity: chronic inflammation, trained immunity, and systemic immune dysregulation.Frontiers in immunology · 2026Review
- Impact of Abdominal Obesity on Frailty Development: A Web-Based Survey Using a Smartphone Health App.Geriatrics (Basel, Switzerland) · 2025Article
- A review of mitochondrial dysfunction in diabetic sarcopenia: Mechanisms, diagnosis, and treatment approaches.The Journal of international medical research · 2025Review
- No independent association between dietary calcium/vitamin D and appendicular lean mass index in middle-aged women: NHANES cross-sectional analysis (2011-2018).Scientific reports · 2025Article
- A comprehensive review of dietary supplements mission-specific health and performance enhancement in military soldiers.Food science and biotechnology · 2025Review
- Review
- Metabolic syndrome worsens sarcopenia and reduces nutritional therapy benefits in advanced gastric cancer.Frontiers in nutrition · 2025Article
- Bridging the Gap: Supplements Strategies from Experimental Research to Clinical Applications in Sarcopenic Obesity.Current issues in molecular biology · 2024Review
- Exploring the multifaceted role of ginkgolides and bilobalide fromFood science and biotechnology · 2024Review
- Irisin and Its Role in Postmenopausal Osteoporosis and Sarcopenia.Biomedicines · 2024Review
- Zinc, Magnesium and Vitamin K Supplementation in Vitamin D Deficiency: Pathophysiological Background and Implications for Clinical Practice.Nutrients · 2024Review
- Associations of sarcopenia, obesity, and metabolic health with the risk of urinary incontinence in U.S. adult women: a population-based cross-sectional study.Frontiers in nutrition · 2024Article
- Preventive effects of a nutraceutical mixture of berberine, citrus and apple extracts on metabolic disturbances in Zucker fatty rats.PloS one · 2024Article
- Physical exercise and irisin: managing obesity and related comorbidities.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
- The impact of dietary interventions on polycystic ovary syndrome patients with a BMI ≥25 kg/mReproductive medicine and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenic obesity, low muscle mass, and high body fat are growing health concerns in the aging population. This review highlights the need for standardized criteria and explores nutraceuticals as potential therapeutic agents. Sarcopenic obesity is associated with insulin resistance, inflammation, hormonal changes, and reduced physical activity. These factors lead to impaired muscle activity, intramuscular fat accumulation, and reduced protein synthesis, resulting in muscle catabolism and increased fat mass. Myostatin and irisin are myokines that regulate muscle synthesis and energy expenditure, respectively. Nutritional supplementation with vitamin D and calcium is recommended for increasing muscle mass and reducing body fat content. Testosterone therapy decreases fat mass and improves muscle strength. Vitamin K, specifically menaquinone-4 (MK-4), improves mitochondrial function and reduces muscle damage. Irisin is a hormone secreted during exercise that enhances oxidative metabolism, prevents insulin resistance and obesity, and improves bone quality. Low-glycemic-index diets and green cardamom are potential methods for managing sarcopenic obesity. In conclusion, along with exercise and dietary support, nutraceuticals, such as vitamin D, calcium, vitamin K, and natural agonists of irisin or testosterone, can serve as promising future therapeutic alternatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.